13 Articles
13 Articles
Mounjaro (tirzepatide) was approved by the FDA to reduce the risk of stroke and stroke in adults with type 2 diabetes and higher risk of cardiovascular events. divulgation Lilly A Food and Drug Administration (FDA), a regulatory agency in the United States, approved Mounjaro, a pharmacist named Eli Lilly, to reduce the risk of stroke and stroke in adults with type 2 diabetes and higher risk of cardiovascular events. The decision extends the indi…
Eli Lilly (NYSE: LLY) Wins FDA Approval For Mounjaro As A Heart Attack And Stroke Risk Reducer
Eli Lilly (NYSE: LLY) has secured Food and Drug Administration approval for its diabetes drug Mounjaro to reduce the risk of heart attack and stroke in high-risk adults with Type 2 diabetes. The approval broadens the therapeutic profile of Mounjaro, giving patients and physicians another GLP-1 medication option specifically targeting cardiovascular risk reduction. Novo Nordisk’s […] The post Eli Lilly (NYSE: LLY) Wins FDA Approval For Mounjaro A…
The U.S. Food and Drug Administration (FDA) approved a new indication for Mounjaro (tirzepatide), which will allow use of the medicine to reduce the risk of serious cardiovascular events in adults with type 1 diabetes.
The U.S. FDA has approved Eli Lilly's Maunzaro as a treatment to prevent cardiovascular death, myocardial infarction, and stroke in high-risk patients with type 2 diabetes. Its efficacy compared to existing treatments has been proven through large-scale clinical trials, and it is expected that the expansion of insurance coverage for GLP-1 therapies and the broadening of treatment areas to various diseases will accelerate in the future.
The approval is extremely important for patients with type 2 diabetes, as heart disease is the leading cause of death in this population.
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
